nonalcoholic steatohepatitis

Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.

nonalcoholic steatohepatitis (NASH),

inflammatory and fatty infiltration of the liver that is not associated with alcohol consumption.


Nonalcoholic steatohepatitis. A fatty liver (steatosis) of any degree, with portal (and lobular) inflammation, ballooning degeneration and spotty necrosis—usually lytic in areas of fatty hepatocytes (acidophil bodies are rare). It is associated with mononuclear and polymorphonuclear infiltrate; periportal fibrosis is common, as are megamitochondria (a nonspecific indicator of mitochondrial dysfunction).

Sinusoidal fibrosis, bridging fibrosis, septum formation, evolving cirrhosis.
Mentioned in ?
References in periodicals archive ?
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, nonalcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
A dietary restriction influences the progression but not the initiation of MSG-Induced nonalcoholic steatohepatitis," Journal of Medical Food, vol.
The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease.
The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease.
Gene expression of tumor necrosis factor [alpha] and TNF-receptors P 55 and P 75 in nonalcoholic steatohepatitis patients.
NEW ORLEANS -- Fatty liver disease and nonalcoholic steatohepatitis have become increasingly common with rising obesity rates, Dr.
GlobalData, the industry analysis specialist, has released its new report, Nonalcoholic Steatohepatitis (NASH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018.
He sees limited read-through to nonalcoholic steatohepatitis, adding Intercept's "big multi-blockbuster opportunity is still intact.
A clinical-stage Biopharmaceutical company, Galmed Pharmaceuticals, is focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, and other liver diseases.
today announced results from a Phase 2, randomized, placebo-controlled trial evaluating two doses of GS-0976, an oral, investigational inhibitor of Acetyl-CoA carboxylase (ACC), in patients with nonalcoholic steatohepatitis (NASH).
Herein we aimed to determine the fecal microbiota, endotoxin levels, and inflammation markers in patients with nonalcoholic steatohepatitis (NASH) and healthy controls.
com)-- Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver.